(2S)-5-[2-[2-[2-[[2-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(3S,12S,15S,18S,21R,24S,26R)-21-benzyl-18-(3-carbamimidamidopropyl)-12-carbamoyl-26-hydroxy-15-(1H-indol-3-ylmethyl)-2,6,14,17,20,23-hexaoxo-1,7,13,16,19,22-hexazabicyclo[22.3.0]heptacosan-3-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-hydroxy-5-imino-1-oxopentan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-5-oxo-2-[16-(1H-tetrazol-5-yl)hexadecanoylamino]pentanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-5-[2-[2-[2-[[2-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(3S,12S,15S,18S,21R,24S,26R)-21-benzyl-18-(3-carbamimidamidopropyl)-12-carbamoyl-26-hydroxy-15-(1H-indol-3-ylmethyl)-2,6,14,17,20,23-hexaoxo-1,7,13,16,19,22-hexazabicyclo[22.3.0]heptacosan-3-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-hydroxy-5-imino-1-oxopentan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-5-oxo-2-[16-(1H-tetrazol-5-yl)hexadecanoylamino]pentanoic acid
• 化学式: C₉₈H₁₅₂N₃₀O₂₃
• 分子量: 2118.47
• InChiKey: BPFVYPFHJGOZAA-VGROMVTCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  151
• 可旋转键数：
  66
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  833
• 氢给体数：
  28
• 氢受体数：
  29

文献信息

• Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity
  申请人：Wulff Birgitte Schjellerup

  公开号：US20100022446A1

  公开（公告）日：2010-01-28

  The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.

  本发明涉及一种新型肽化合物，其能有效调节一个或多个黑色素皮质素受体类型，并且涉及使用这些化合物进行治疗的方法，包括将这些化合物用于需要治疗的患者的治疗方法以及将这些化合物用于制造药物。本发明的化合物在治疗肥胖以及与肥胖相关的各种疾病或病症方面具有特别的兴趣。
• Novel Peptides for Use in the Treatment of Obesity
  申请人：Sensfuss Ulrich

  公开号：US20090203581A1

  公开（公告）日：2009-08-13

  The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.

  本发明涉及一种新型肽化合物，其有效地调节一种或多种黑色素皮质素受体类型，涉及该化合物在治疗中的使用，涉及包括向需要该化合物的患者施用该化合物的治疗方法，以及涉及该化合物在制药中的使用。本发明的化合物特别适用于肥胖症的治疗以及与肥胖症相关的各种疾病或病状。